Who is sponsoring NCT03878199?

NCT03878199 is sponsored by Ohio State University Comprehensive Cancer Center.

What drugs are being tested in NCT03878199?

Interventions in NCT03878199: Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib.

What condition does NCT03878199 study?

NCT03878199 studies Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia.

Is NCT03878199 still recruiting?

NCT03878199 is currently completed. Last updated 15 September 2025.

Last reviewed 2025-09-15 · How we verify

NCT03878199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Completed Phase 1, PHASE2 Last updated 15 September 2025

What this trial tests

Phase 1, PHASE2 trial testing Allogeneic Hematopoietic Stem Cell Transplantation in Essential Thrombocythemia in 12 participants. Completed in 27 February 2025.

Timeline

20 February 2019

Primary endpoint
27 February 2025

27 February 2025

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	20 February 2019
Primary completion	27 February 2025
Estimated completion	27 February 2025
Sites	3 locations across United States

Drugs / interventions tested

Allogeneic Hematopoietic Stem Cell Transplantation — full drug profile →
Liposome-encapsulated Daunorubicin-Cytarabine — full drug profile →
Ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

Essential Thrombocythemia — all drugs for Essential Thrombocythemia →
Myelofibrosis — all drugs for Myelofibrosis →
Myeloproliferative Neoplasm — all drugs for Myeloproliferative Neoplasm →
Polycythemia Vera — all drugs for Polycythemia Vera →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Essential Thrombocythemia or Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, et al · · 2021 · cited 50× · PMID 34944059 · DOI 10.3390/cells10123551
JAK/STAT in leukemia: a clinical update.
Liang D, Wang Q, Zhang W, Tang H, et al · · 2024 · cited 38× · PMID 38273387 · DOI 10.1186/s12943-023-01929-1
Nanocarriers as Magic Bullets in the Treatment of Leukemia.
Houshmand M, Garello F, Circosta P, Stefania R, et al · · 2020 · cited 35× · PMID 32041219 · DOI 10.3390/nano10020276
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.
Mendez LM, Posey RR, Pandolfi PP. · · 2019 · cited 31× · PMID 31781488 · DOI 10.3389/fonc.2019.01162
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A. · · 2021 · cited 22× · PMID 34073410 · DOI 10.3390/cancers13112611
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Tokareva K, Reid P, Yang V, Liew D, et al · · 2023 · cited 20× · PMID 37596779 · DOI 10.1080/1744666x.2023.2249237
Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G, DiNardo CD. · · 2019 · cited 18× · PMID 31808888 · DOI 10.1182/hematology.2019000059
Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.
Huang X, Lin H, Huang F, Xie Y, et al · · 2019 · cited 17× · PMID 31853234 · DOI 10.1177/1559325819887048

Verify or expand the search:

Other trials of Allogeneic Hematopoietic Stem Cell Transplantation

Trials testing the same drug.

NCT06954987 — Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell · Phase 2 · not yet recruiting
NCT04579523 — ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Tr · Phase 1 · not yet recruiting
NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
NCT07228624 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas · Phase 2 · recruiting

Other recruiting trials for Essential Thrombocythemia

Currently open trials in the same condition.

NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
NCT06734637 — Efficacy and Safety of Peginterferon in ET and PV. · NA · recruiting
NCT06456346 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) · Phase 3 · recruiting
NCT06361641 — Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes · NA · recruiting
NCT06378437 — A Study of GLB-001 in Patients With Myeloid Malignancies · Phase 1 · recruiting

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03878199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
Last refreshed: 15 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03878199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing